RxDoctor Payments Data

Stephanie Morton, MD

Family Medicine · Cleburne, TXNPI 1669470076

Payments from drug & device makers

$1,268in general payments, 2019–2025

Across 93 payments — averaging $13.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$265
  • Pfizer$207
  • Amarin Pharma, Inc.$153
  • Astellas Pharma US Inc$145
  • AbbVie$131
  • GSK$129
  • plus $238 from 12 others

What the payments were for

  • Food & beverage$1,268100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,268 in reported general payments places this provider in the 65th percentile of 8,760 family medicine providers in Texas.

See all family medicine providers in Texas

Medicare billing

Part B allowed, 2024
$64,151
Medicare patients
226
Services billed
1,033

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban99$88,461
JardianceEmpagliflozin73$85,350
OzempicSemaglutide28$47,047
Trelegy ElliptaFluticasone/Umeclidin/Vilanter60$44,532
XifaxanRifaximin12$35,051
MyrbetriqMirabegron33$32,493
XareltoRivaroxaban21$31,977
ProliaDenosumab14$24,564
MounjaroTirzepatide22$24,201
Tresiba Flextouch U-200Insulin Degludec18$21,748
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog29$20,198
Janumet XrSitagliptin Phos/Metformin Hcl19$17,871
SymbicortBudesonide/Formoterol Fumarate31$14,660
GlyxambiEmpagliflozin/Linagliptin13$13,063
JanuviaSitagliptin Phosphate11$11,996

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Glyxambi$27$98,41386 claims
PfizerEliquis$207$88,46199 claims
Novo NordiskOzempic, Rybelsus$12$58,99939 claims
GSKTrelegy Ellipta, Breo Ellipta$129$52,31674 claims
MerckJanumet Xr, Januvia, Janumet$23$38,74142 claims
Astellas Pharma US IncMyrbetriq$145$32,49333 claims
AmgenProlia$12$24,56414 claims
Lilly USA, LLCMounjaro$11$24,20122 claims
AstraZenecaSymbicort, Farxiga$265$23,35244 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 8,760 family medicine providers in Texas.

Other family medicine in Cleburne

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →